<?xml version="1.0" encoding="UTF-8"?>
<ref id="B93-biomedicines-08-00060">
 <label>93.</label>
 <element-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Wu</surname>
    <given-names>Y.</given-names>
   </name>
   <name>
    <surname>He</surname>
    <given-names>J.</given-names>
   </name>
   <name>
    <surname>An</surname>
    <given-names>Y.</given-names>
   </name>
   <name>
    <surname>Wang</surname>
    <given-names>X.</given-names>
   </name>
   <name>
    <surname>Liu</surname>
    <given-names>Y.</given-names>
   </name>
   <name>
    <surname>Yan</surname>
    <given-names>S.</given-names>
   </name>
   <name>
    <surname>Ye</surname>
    <given-names>X.</given-names>
   </name>
   <name>
    <surname>Qi</surname>
    <given-names>J.</given-names>
   </name>
   <name>
    <surname>Zhu</surname>
    <given-names>S.</given-names>
   </name>
   <name>
    <surname>Yu</surname>
    <given-names>Q.</given-names>
   </name>
   <etal/>
  </person-group>
  <article-title>Recombinant Newcastle disease virus (NDV/Anh-IL-2) expressing human IL-2 as a potential candidate for suppresses growth of hepatoma therapy</article-title>
  <source>J. Pharmacol. Sci.</source>
  <year>2016</year>
  <volume>132</volume>
  <fpage>24</fpage>
  <lpage>30</lpage>
  <pub-id pub-id-type="doi">10.1016/j.jphs.2016.03.012</pub-id>
  <pub-id pub-id-type="pmid">27174862</pub-id>
 </element-citation>
</ref>
